Seres Therapeutics Inc.'s stock-joltingly failed phase II study with SER-109 was not the first or only placebo-controlled microbiome trial against recurrent Clostridium difficile infection (CDI), and better (currently embargoed) news will roll out during scientific sessions this fall from Rebiotix Inc., with RBX2660, CEO Lee Jones told BioWorld Today.